Kimelman & Baird LLC Invests $1.31 Million in Pfizer Inc. (NYSE:PFE)

Kimelman & Baird LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 46,941 shares of the biopharmaceutical company’s stock, valued at approximately $1,313,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Gilbert & Cook Inc. grew its stake in shares of Pfizer by 3.8% during the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 945 shares in the last quarter. NEOS Investment Management LLC boosted its holdings in Pfizer by 34.8% during the fourth quarter. NEOS Investment Management LLC now owns 80,004 shares of the biopharmaceutical company’s stock worth $2,303,000 after purchasing an additional 20,651 shares during the last quarter. Rhenman & Partners Asset Management AB bought a new position in Pfizer in the fourth quarter valued at $16,698,000. Peapack Gladstone Financial Corp lifted its position in Pfizer by 13.7% during the 4th quarter. Peapack Gladstone Financial Corp now owns 592,714 shares of the biopharmaceutical company’s stock worth $17,064,000 after buying an additional 71,514 shares in the last quarter. Finally, Nicholas Company Inc. acquired a new position in shares of Pfizer during the 4th quarter worth about $6,464,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Wells Fargo & Company boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Barclays upped their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Performance

PFE opened at $29.09 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The business has a fifty day simple moving average of $29.31 and a 200 day simple moving average of $28.30. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $34.11. The company has a market capitalization of $164.84 billion, a PE ratio of -484.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.68.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the previous year, the business posted $0.67 earnings per share. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.